Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

MPLT vs ACNB

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MPLT
MapLight Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • USA
Market Cap$1.33B
5Y Perf.+10.2%
ACNB
ACNB Corporation

Banks - Regional

Financial ServicesNASDAQ • US
Market Cap$544M
5Y Perf.+13.0%

MPLT vs ACNB — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MPLT logoMPLT
ACNB logoACNB
IndustryBiotechnologyBanks - Regional
Market Cap$1.33B$544M
Revenue (TTM)$0.00$170M
Net Income (TTM)$-103M$37M
Gross Margin73.7%
Operating Margin27.3%
Forward P/E9.8x
Total Debt$7M$329M
Cash & Equiv.$38M$21M

Quick Verdict: MPLT vs ACNB

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ACNB leads in 3 of 5 categories, making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. MapLight Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
MPLT
MapLight Therapeutics, Inc.
The Defensive Pick

MPLT is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Low D/E 5.7%, current ratio 7.20x
  • current ratio 7.20x
  • Lower D/E ratio (5.7% vs 78.3%)
Best for: sleep-well-at-night and defensive
ACNB
ACNB Corporation
The Banking Pick

ACNB carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 28.9%, EPS growth -3.5%
  • 179.5% 10Y total return vs MPLT's 62.6%
  • 21.7% margin vs MPLT's 3.3%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
Quality / MarginsACNB logoACNB21.7% margin vs MPLT's 3.3%
Stability / SafetyMPLT logoMPLTLower D/E ratio (5.7% vs 78.3%)
DividendsACNB logoACNB2.7% yield; 8-year raise streak; the other pay no meaningful dividend
Momentum (1Y)MPLT logoMPLT+62.6% vs ACNB's +22.7%
Efficiency (ROA)ACNB logoACNB1.1% ROA vs MPLT's -69.7%, ROIC 5.3% vs -153.7%

MPLT vs ACNB — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MPLTMapLight Therapeutics, Inc.

Segment breakdown not available.

ACNBACNB Corporation
FY 2025
Mortgage Banking
29.0%$5M
Deposit Account
26.7%$5M
Fiduciary and Trust
24.7%$4M
ATM Service Charges and Debit Card Transactions
19.6%$4M

MPLT vs ACNB — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLACNBLAGGINGMPLT

Income & Cash Flow (Last 12 Months)

Insufficient data to determine a leader in this category.

ACNB and MPLT operate at a comparable scale, with $170M and $0 in trailing revenue.

MetricMPLT logoMPLTMapLight Therapeu…ACNB logoACNBACNB Corporation
RevenueTrailing 12 months$0$170M
EBITDAEarnings before interest/tax-$108M$53M
Net IncomeAfter-tax profit-$103M$37M
Free Cash FlowCash after capex-$113M$51M
Gross MarginGross profit ÷ Revenue+73.7%
Operating MarginEBIT ÷ Revenue+27.3%
Net MarginNet income ÷ Revenue+21.7%
FCF MarginFCF ÷ Revenue+30.9%
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year+35.1%
Insufficient data to determine a leader in this category.

Valuation Metrics

Evenly matched — MPLT and ACNB each lead in 1 of 2 comparable metrics.
MetricMPLT logoMPLTMapLight Therapeu…ACNB logoACNBACNB Corporation
Market CapShares × price$1.3B$544M
Enterprise ValueMkt cap + debt − cash$1.3B$853M
Trailing P/EPrice ÷ TTM EPS-15.66x14.61x
Forward P/EPrice ÷ next-FY EPS est.9.75x
PEG RatioP/E ÷ EPS growth rate1.32x
EV / EBITDAEnterprise value multiple16.03x
Price / SalesMarket cap ÷ Revenue3.20x
Price / BookPrice ÷ Book value/share10.53x1.29x
Price / FCFMarket cap ÷ FCF10.36x
Evenly matched — MPLT and ACNB each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

ACNB leads this category, winning 5 of 8 comparable metrics.

ACNB delivers a 9.2% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-2 for MPLT. MPLT carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACNB's 0.78x. On the Piotroski fundamental quality scale (0–9), ACNB scores 5/9 vs MPLT's 4/9, reflecting solid financial health.

MetricMPLT logoMPLTMapLight Therapeu…ACNB logoACNBACNB Corporation
ROE (TTM)Return on equity-2.1%+9.2%
ROA (TTM)Return on assets-69.7%+1.1%
ROICReturn on invested capital-153.7%+5.3%
ROCEReturn on capital employed-83.9%+2.5%
Piotroski ScoreFundamental quality 0–945
Debt / EquityFinancial leverage0.06x0.78x
Net DebtTotal debt minus cash-$32M$308M
Cash & Equiv.Liquid assets$38M$21M
Total DebtShort + long-term debt$7M$329M
Interest CoverageEBIT ÷ Interest expense1.16x
ACNB leads this category, winning 5 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

ACNB leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ACNB five years ago would be worth $20,536 today (with dividends reinvested), compared to $16,263 for MPLT. Over the past 12 months, MPLT leads with a +62.6% total return vs ACNB's +22.7%. The 3-year compound annual growth rate (CAGR) favors ACNB at 24.1% vs MPLT's 17.6% — a key indicator of consistent wealth creation.

MetricMPLT logoMPLTMapLight Therapeu…ACNB logoACNBACNB Corporation
YTD ReturnYear-to-date+62.6%+12.1%
1-Year ReturnPast 12 months+62.6%+22.7%
3-Year ReturnCumulative with dividends+62.6%+91.0%
5-Year ReturnCumulative with dividends+62.6%+105.4%
10-Year ReturnCumulative with dividends+62.6%+179.5%
CAGR (3Y)Annualised 3-year return+17.6%+24.1%
ACNB leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

ACNB leads this category, winning 1 of 1 comparable metric.

ACNB currently trades 97.5% from its 52-week high vs MPLT's 88.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMPLT logoMPLTMapLight Therapeu…ACNB logoACNBACNB Corporation
Beta (5Y)Sensitivity to S&P 5000.68x
52-Week HighHighest price in past year$33.28$53.93
52-Week LowLowest price in past year$16.34$40.15
% of 52W HighCurrent price vs 52-week peak+88.0%+97.5%
RSI (14)Momentum oscillator 0–10059.257.2
Avg Volume (50D)Average daily shares traded264K62K
ACNB leads this category, winning 1 of 1 comparable metric.

Analyst Outlook

Insufficient data to determine a leader in this category.

Consensus price targets imply 15.4% upside for MPLT (target: $34) vs 10.3% for ACNB (target: $58). ACNB is the only dividend payer here at 2.66% yield — a key consideration for income-focused portfolios.

MetricMPLT logoMPLTMapLight Therapeu…ACNB logoACNBACNB Corporation
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$33.80$58.00
# AnalystsCovering analysts2
Dividend YieldAnnual dividend ÷ price+2.7%
Dividend StreakConsecutive years of raises8
Dividend / ShareAnnual DPS$1.40
Buyback YieldShare repurchases ÷ mkt cap0.0%+2.1%
Insufficient data to determine a leader in this category.
Key Takeaway

ACNB leads in 3 of 6 categories — strongest in Profitability & Efficiency and Total Returns. 1 category is tied.

Best OverallACNB Corporation (ACNB)Leads 3 of 6 categories
Loading custom metrics...

MPLT vs ACNB: Frequently Asked Questions

9 questions · data-driven answers · updated daily

01

Is MPLT or ACNB a better buy right now?

ACNB Corporation (ACNB) offers the better valuation at 14.

6x trailing P/E (9. 8x forward), making it the more compelling value choice. Analysts rate ACNB Corporation (ACNB) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — MPLT or ACNB?

Over the past 5 years, ACNB Corporation (ACNB) delivered a total return of +105.

4%, compared to +62. 6% for MapLight Therapeutics, Inc. (MPLT). Over 10 years, the gap is even starker: ACNB returned +179. 5% versus MPLT's +62. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — MPLT or ACNB?

On balance sheet safety, MapLight Therapeutics, Inc.

(MPLT) carries a lower debt/equity ratio of 6% versus 78% for ACNB Corporation — giving it more financial flexibility in a downturn.

04

Which is growing faster — MPLT or ACNB?

On earnings-per-share growth, the picture is similar: ACNB Corporation grew EPS -3.

5% year-over-year, compared to -39. 6% for MapLight Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — MPLT or ACNB?

ACNB Corporation (ACNB) is the more profitable company, earning 21.

7% net margin versus 0. 0% for MapLight Therapeutics, Inc. — meaning it keeps 21. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACNB leads at 27. 3% versus 0. 0% for MPLT. At the gross margin level — before operating expenses — ACNB leads at 73. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is MPLT or ACNB more undervalued right now?

Analyst consensus price targets imply the most upside for MPLT: 15.

4% to $33. 80.

07

Which pays a better dividend — MPLT or ACNB?

In this comparison, ACNB (2.

7% yield) pays a dividend. MPLT does not pay a meaningful dividend and should not be held primarily for income.

08

Is MPLT or ACNB better for a retirement portfolio?

For long-horizon retirement investors, ACNB Corporation (ACNB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

68), 2. 7% yield, +179. 5% 10Y return). Both have compounded well over 10 years (ACNB: +179. 5%, MPLT: +62. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between MPLT and ACNB?

These companies operate in different sectors (MPLT (Healthcare) and ACNB (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MPLT is a small-cap quality compounder stock; ACNB is a small-cap high-growth stock. ACNB pays a dividend while MPLT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

MPLT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ACNB

High-Growth Quality Leader

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 13%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.